Physician profile
Staci Clabough
NPI 1215495700
$1,067.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $950 · 2022: $118.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $286.23 | 2021-2022 | |
| Boston Scientific Corporation | $149.52 | 2021-2022 | |
| Medtronic, INC. | $108.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.45 | 2021 | |
| Scilex Pharmaceuticals INC. | $65.14 | 2021 | |
| Ibsa Pharma INC. | $62.76 | 2021 | |
| Almatica Pharma LLC | $60.37 | 2021 | |
| Biodelivery Sciences International, INC. | $51.90 | 2021 | |
| Collegium Pharmaceutical, INC. | $51.36 | 2021 | |
| Redhill Biopharma INC. | $40.16 | 2021 | |
| Pfizer INC. | $37.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $36.66 | 2021 | |
| Pacira Therapeutics, INC. | $16.30 | 2021 | |
| Virtus Pharmaceuticals LLC | $14.40 | 2021 | |
| Forte Bio-Pharma LLC | $10.14 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Clabough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.